These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 17494940)
1. Interleukin-12/23 monoclonal antibody for psoriasis. Okamoto H; Momohara S N Engl J Med; 2007 May; 356(19):2003; author reply 2003. PubMed ID: 17494940 [No Abstract] [Full Text] [Related]
2. Prospective new biologic therapies for psoriasis and psoriatic arthritis. Mortel MR; Emer J J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145 [TBL] [Abstract][Full Text] [Related]
3. Ustekinumab poised to enter the psoriasis market. Schmidt C Nat Biotechnol; 2008 Dec; 26(12):1317-8. PubMed ID: 19060851 [No Abstract] [Full Text] [Related]
4. New biologics for psoriasis and psoriatic arthritis. Rozenblit M; Lebwohl M Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Kimball AB; Gordon KB; Langley RG; Menter A; Chartash EK; Valdes J; Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176 [TBL] [Abstract][Full Text] [Related]
6. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study. Gniadecki R; Bang B; Sand C Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308 [No Abstract] [Full Text] [Related]
7. Is there a need for new agents with novel mechanisms of action in psoriatic arthritis? Orr C; Veale DJ Ann Rheum Dis; 2014 Jun; 73(6):951-3. PubMed ID: 24790066 [No Abstract] [Full Text] [Related]
14. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940 [TBL] [Abstract][Full Text] [Related]
15. [Our experience with infliximab in reclacitrant cases of psoriasis]. Pereiro M; González-Vilas D; Sánchez-Aguilar D; Toribio J Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():43-7. PubMed ID: 19080991 [TBL] [Abstract][Full Text] [Related]
16. Briakinumab. Lima XT; Abuabara K; Kimball AB; Lima HC Expert Opin Biol Ther; 2009 Aug; 9(8):1107-13. PubMed ID: 19569977 [TBL] [Abstract][Full Text] [Related]
17. When anti-TNF fails, anti-IL12-23 is an alternate option in psoriasis and psoriatic arthritis. Golmia RP; Martins AH; Scheinberg M Rev Bras Reumatol; 2014; 54(3):247-9. PubMed ID: 25054605 [TBL] [Abstract][Full Text] [Related]
18. Anti-interleukin-12 antibody for active Crohn's disease. Kolls JK; Zhang Z N Engl J Med; 2005 Feb; 352(6):627-8; author reply 627-8. PubMed ID: 15706644 [No Abstract] [Full Text] [Related]
19. Risankizumab: First Global Approval. McKeage K; Duggan S Drugs; 2019 Jun; 79(8):893-900. PubMed ID: 31098898 [TBL] [Abstract][Full Text] [Related]
20. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Ding C; Xu J; Li J Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]